Posted Tue, Apr, 29,2014
Published today in Journal of Central Nervous System Disease is a new review article by Robert Hoepner, Simon Faissner, Anke Salmen, Ralf Gold and Andrew Chan. Read more about this paper below:
Title
Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis
Abstract
Natalizumab (Nat) is a humanized monoclonal antibody used for the treatment of relapsing multiple sclerosis (MS). Nat inhibits lymphocyte migration via the blood brain barrier (BBB) by blockage of an integrin adhesion molecule, very late antigen 4. During the phase III clinical trials, it was shown that Nat reduces disease activity and prevents disability progression. In addition, several smaller studies indicate a positive influence of Nat on cognition, depression, fatigue, and quality of life (Qol). Therapeutic efficacy has to be weighed against the risk of developing potentially fatal progressive multifocal leukoencephalopathy (PML), an opportunistic infection by JC-virus (JCV) with an incidence of 3.4/1000 (95% CI 3.08–3.74) in Nat treated MS patients. In this review article, we will review data on the presumed mechanism of Nat action, clinical and paraclinical efficacy parameters, and adverse drug reactions with a special focus on PML.
Click here to learn more about the article, download it and comment
Posted in: Articles Published
News Categories
Thu 08 Oct, 2015
Published This Week (5th - 9th October)Thu 08 Oct, 2015
Biomarker Insights Paper Endorsed by Editor in ChiefWed 07 Oct, 2015
Interview with Professor Jamie DaviesMy experience with Int J Tryptophan Research has been excellent. The editors and reviewers were most helpful and very "open" intellectually given we were proposing a novel and counter-intuitive hypothesis. The administrative staff have been patient, quick, helpful and friendly. I would and have recommended this group of journals to colleagues.
Facebook Google+ Twitter
Pinterest Tumblr YouTube